A Peptide Merger That Reflects Biotech’s New Priorities

Completed in Nov 2025, the Salarius and Decoy deal creates Decoy Therapeutics with $14M and an AI-first peptide platform

3 Feb 2026

A newly completed merger is rippling through the US peptide therapeutics space, and the message is unmistakable. In today’s tighter biotech market, speed and smarter design matter more than scale.

Finalized in November 2025, the combination of Salarius Pharmaceuticals and Decoy Therapeutics brings together two companies with different pasts and a shared future. Salarius built its reputation on traditional oncology programs. Decoy, by contrast, focused on computational tools to design peptide conjugate drugs more efficiently. The merged company will operate as Decoy Therapeutics, a name that reflects where its ambitions now lie.

At the center of the strategy is Decoy’s IMP3ACT platform. The system uses advanced computing to design and optimize peptide conjugates before they reach the lab. The promise is straightforward. Shorter discovery timelines, lower early risk, and drug candidates that are more appealing to partners and investors. Executives say the platform allows teams to move from concept to optimized molecules far faster than conventional discovery approaches.

The deal’s financial structure supports that pivot. A public offering completed alongside the merger left the company with roughly $14 million in pro forma cash. That runway is expected to fund further platform development and early-stage programs. Leadership changes reinforce the shift, with Decoy’s founders stepping into key roles at the combined company.

Initially, Decoy Therapeutics plans to focus on viral diseases and select gastrointestinal cancers. These are areas where peptide conjugates are drawing attention for their ability to deliver targeted therapies with greater precision. While the merger does not instantly change the competitive landscape, it reflects a broader recalibration underway across biotech.

Smaller firms are increasingly moving away from single-asset bets and toward scalable platforms that can generate multiple candidates. The trend aligns with constrained funding and growing interest from large pharmaceutical partners seeking repeatable innovation.

There are still hurdles ahead. Digitally designed peptide conjugates must prove they can be manufactured at scale, clear regulators, and perform reliably in the clinic. Even so, the direction is hard to miss.

For industry watchers, this merger is less about size and more about momentum. As Decoy Therapeutics moves forward, it offers a clear example of how smarter discovery models may define the next chapter of peptide drug development.